A new four-month prospective observational study assessed migraine-related disability and work productivity among employed adults while exploring their coping strategies, workplace experiences, and perceived workplace accommodations. Conducted between February 2026 and May 2026 at the neurology outpatient department of a tertiary care teaching hospital and its associated employee wellness program, the research demonstrates that tracking and managing migraine triggers leads to measurable drops in both absenteeism and presenteeism.
Migraine remains a driver of functional impairment among working-age individuals. Researchers designed this mixed-methods investigation to evaluate how clinical improvements in attack frequency and pain severity translate directly into daily job performance and overall economic productivity.
Clinical Evaluation and Productivity Metrics at Tertiary Hospital
The study enrolled 150 employed adults aged 18 to 55 years who possessed an established clinical diagnosis of migraine based on the International Classification of Headache Disorders, 3rd Edition (ICHD-3). The cohort consisted largely of women, accounting for 68.0 percent of participants, with a mean age of 34.8 ± 7.2 years. To qualify, participants had to be employed either full-time or part-time and experience at least two migraine episodes per month during the three months preceding enrollment.
#Migraine is an invisible disability! People with migraine loss on average 10 work days/year causing 💲💲💲 in each country's economy! Spread the word! Visit our website for more info! https://t.co/7AfvAIYXdl #migraineawareness2021 #migraineawareness #mham #mham2021 #neurology pic.twitter.com/YIevoIs3CY
Investigators tracked participants using standardized instruments, including the Migraine Disability Assessment Scale (MIDAS) and the Work Productivity and Activity Impairment Questionnaire (WPAI). Pain severity was gauged using the Visual Analog Scale (VAS). At the four-month follow-up evaluation, researchers recorded notable reductions in monthly migraine frequency, attack duration, pain severity, and overall daily activity impairment compared to baseline metrics.
Ethical Approval and Participant Retention Protocols
Prior to patient recruitment, the study protocol secured formal ethical clearance. The Ethics Committee of N.K.P. Salve Institute of Medical Sciences and Research Centre and Lata Mangeshkar Hospital granted approval on January 29, 2026, under reference number NKPSIMS & RC and LMH/IEC/19/2026. All enrolled individuals provided written informed consent before completing baseline assessments.
Study retention remained high throughout the four-month observation window. All 150 participants completed the final follow-up assessment without any withdrawals or loss to follow-up.
Qualitative Insights From Employee Interviews
Beyond quantitative metrics, researchers conducted semi-structured interviews with 30 purposively selected participants from the main cohort. These qualitative sessions explored workplace experiences, trigger management, and psychological impacts. Investigators continued interviews until reaching thematic saturation after 30 sessions, noting that no new codes emerged during the final five interviews.
The qualitative data identified coping strategies, trigger management, workplace accommodations, psychological impact, and social support as major themes.
Frequently Asked Questions About the Migraine Productivity Study
What specific questionnaires did researchers use to measure productivity loss?
Investigators utilized the Work Productivity and Activity Impairment Questionnaire to track absenteeism and presenteeism, alongside the Migraine Disability Assessment Scale to measure overall functional disability at baseline and the four-month follow-up mark.
Who was eligible to participate in the observation period?
The study included adults aged 18 to 55 years who worked either full-time or part-time, had a confirmed ICHD-3 migraine diagnosis, and experienced a minimum of two migraine episodes per month during the three months leading up to the trial.
Where was the clinical research conducted?
The trial took place between February 2026 and May 2026 within the neurology outpatient department of a tertiary care teaching hospital and its associated employee wellness program.
Worth a look